India, Aug. 10 -- image credit- freepik

Biodeal Pharmaceuticals, one of India's leading specialty pharmaceutical Contract Development and Manufacturing Organisations (CDMOs), has announced a growth investment of Rs 385 crore from RMB Capitalworks, a joint venture between Rand Merchant Bank and Capitalworks Group.

The investment marks a significant milestone in Biodeal's growth journey and will support the company's next phase of expansion across specialty pharmaceuticals, manufacturing capabilities, and regulated markets.

he investment will support Biodeal's next phase of expansion, strengthening its positions across Asian markets while accelerating growth across CIS, LATAM, Africa and Europe.

"This investment represents much more tha...